2017 saw the arrival of numerous pot stocks on the ASX.
Here's a look at how they have been performing.
The Auscann Group Holdings Ltd (ASX: AC8) share price has gained more than 200 per cent since the company listed in February.
Auscann is involved in the cultivation, manufacture and distribution of cannabinoid medicines.
Botanix Pharmaceuticals Ltd (ASX: BOT), which focuses on dermatology products, also has a hand in the medical cannabis market.
Its share price has gained more than 20 per cent in the past year.
Cannpal Animal Therapeutics Ltd (ASX: CP1) attracted attention when it said it was going to use cannabis to treat pets.
Cannpal, which listed in October, has so far seen its share price rise by about 14 per cent.
Creso Pharma Ltd (ASX: CPH), with a hand in the hemp-based medicines market, has seen its share price rise by more than 280 per cent in the past year.
Hydroponics Company Ltd (ASX: THC), which is involved in medicinal cannabis and the manufacturing and distribution of hydroponics equipment, has seen its share price gain more than 90 per cent since it listed in May.
Medlab Clinical Ltd (ASX: MDC) has not performed as well as others in the sector with its share price dropping by more than 10 per cent over the past year.
But, with the company stating that its Australian manufactured medical cannabis product will be available for prescription in February next year, things may turn around for Medlab.
MGC Pharmaceuticals Ltd (ASX: MXC), another player seeking to crack the lucrative medicinal cannabis market, has seen its share price rise by more than 80 per cent over the past year.
The Zelda Therapeutics Ltd (ASX: ZLD) share price has gained more than 140 per cent in the past year as the company makes inroads with its medicinal cannabis products.
As such, 2017 has been a great year for most of the ASX pot stocks.
And it appears there will be more to come in 2018.
